

From: [Dehdashti, Seameen \(Jean\)](#)
To: "BDV (Barbara Davies)"
Cc: [Dehdashti, Seameen \(Jean\)](#)
Subject: FDA Information Request (IR): BLA 125671/0
Date: Friday, July 06, 2018 8:53:52 AM
Attachments: [image002.png](#)
Importance: High

Dear Barbara,

Reference is made to Novo Nordisk, Inc., original BLA 125671 submission, dated February 27, 2018. We are reviewing your BLA submission for Antihemophilic factor, GlycoPEGylated (STN125671) and have the following information request (IR), outlined in **bold text** below. Please provide your response by Friday, July 20, 2018.

FDA Information Request:

In Section, 3.2.5. of the submission, a (b) (4) method was used to determine the particulate matter of the drug product; however, no detailed description of the assay procedures was provided in the BLA. Please provide the SOP or a detailed description of the test by July 20, 2018.

Please confirm receipt of my e-mail, and do not hesitate to contact me, should you have any questions and/or concerns.

Warm regards,

Jean Dehdashti, MSc, RAC
Regulatory Project Manager

Center for Biologics and Evaluation
Office of Tissues and Advanced Therapies
U.S. Food and Drug Administration
Tel: 240-402-9146
Seameen.Dehdashti@fda.hhs.gov



THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.